调查:英国NHS三家基因实验室未常规共享罕见病诊断所需变异数据
NHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds
The BMJ调查显示,英格兰七家NHS基因组实验室枢纽中有三家未按惯例向ClinVar等公共数据库提交基因变异信息,另四家也存在提交积压或数据缺口。实验室称主要受限于人员配备、政策制定周期及信息技术基础设施;而患者家属与专家警告,这种不完整的共享会在罕见病基因检测中制造结构性盲区,延长诊断不确定性,并浪费公共资金产生的临床数据价值。
Three of England's seven NHS genetics laboratories are failing to routinely share vital information about genetic variants in public databases that helps patients with rare diseases access diagnosis and care, an investigation by The BMJ reveals.
Despite good intentions, the labs say they lack the necessary staff and technology to do so and intend to implement this requirement as soon as possible.
But experts and families say that this failure can lead to prolonged uncertainty for patients suspected of having a rare genetic disease, as well as raising questions about the management and sharing of publicly generated patient data and knowledge in the NHS.
England has seven NHS Genomics Laboratory Hubs (GLHs) that coordinate clinical genomics services in their regions, including testing, diagnosis, treatment and counseling. Since 2024, they have been required to submit variants to public databases, such as ClinVar, under Association for Clinical Genomic Science (ACGS) guidance.
The guidance also sets out why these submissions are so vital: Prompt and accurate molecular diagnosis is crucial, it says, for targeting treatment and optimizing patient care. It is therefore "the professional responsibility of the clinical genomics community to ensure data is shared" appropriately and responsibly.
But information provided by the seven GLHs at the start of 2026—in response to freedom of information requests—indicates that variant sharing is inconsistent, incomplete and in some cases absent.
Three of the seven GLHs—South East (led by Guy's and St Thomas' NHS Foundation Trust), South West (North Bristol NHS Trust), and North East and Yorkshire (The Newcastle upon Tyne Hospitals NHS Foundation Trust)—said they were not routinely submitting variants to ClinVar.
Even among the four hubs routinely submitting variants to ClinVar, there are significant backlogs of unsubmitted variants, as well as inconsistencies and gaps in what is submitted.
Sophie Muir, whose son's variant for a CACNA1C-related disorder wasn't picked up through NHS testing, says, "ClinVar functions as a shared clinical evidence base for variant interpretation. Inconsistent submission practices create structural blind spots, selectively limiting the evidence available for rare disease diagnosis, variant reclassification and research."
Jack Underwood, a forensic psychiatry registrar, agrees, saying "there is a loop that is broken by not submitting to ClinVar," while professor John Sayer, an expert in rare inherited kidney diseases, warns that "patients ultimately are missing out because this isn't happening."
Staffing was the issue most cited by the GLHs as the reason for the delay in implementing routine submission to ClinVar. Some hubs blamed the time taken to develop policies, as well as technology and infrastructure issues. Those GLHs that had not yet implemented routine ClinVar submissions said they planned to do so this year.
Muir, who is also chair of the rare disease charity the Timothy Syndrome Alliance, points out that the GLHs are generating clinically interpreted data in a publicly funded system. "Public funds are going in to pay for genetic testing and then it's not being shared. It's not right," she says.
Sayer agrees that variant sharing maximizes the value of the public investment in genetic testing. "It's privileged information, knowing someone's genetics," he says, "and if they've consented to that being used for the greater good then you're betraying a patient's trust by not allowing that information to be shared."
Clare Turnbull, professor of cancer genetics at the Institute of Cancer Research London, says the delay in variant sharing by GLHs is part of the wider issue of lagging NHS IT systems hobbling progress and innovation.
In the meantime, says Muir, the delay is causing harm to rare disease patients and families like hers. "We don't have time on our side," she says. "Our families, our children, our researchers and clinicians, our patient advocacy organizations and our life sciences need this data."
Publication details
Rare diseases: NHS labs fail to share data vital for diagnosis and care, BMJ finds, The BMJ (2026). DOI: 10.1136/bmj-2026-101004
Journal information: British Medical Journal (BMJ)
Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: NHS labs fail to share data vital for diagnosis and care of rare diseases, investigation finds (2026, October 7) retrieved 7 October 2026 from https://medicalxpress.com/news/2026-10-nhs-labs-vital-diagnosis-rare.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com